Abstract: Spreading depolarizations (SDs) are key drivers of secondary brain injury, yet existing bedside monitoring methods that use electrocorticography (ECoG) analyze electrodes and frequency bands ...
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced the retirement of Robert J. (Bob) Gray, PhD, from his position as Group Statistician, Therapeutics, effective February 28, 2026. Dr. Gray ...
Revised: This Reviewed Preprint has been revised by the authors in response to the previous round of peer review; the eLife assessment and the public reviews have been updated where necessary by the ...
Patients with ECOG performance status of 1 reported worse global health status, quality of life, and physical functioning than those with a status of 0. The RATIONALE-305 trial showed Tevimbra plus ...
At the San Antonio Breast Cancer Symposium, Jennifer Specht, MD, of the University of Washington and Fred Hutch Cancer Center, Seattle, presented results from the ECOG-ACRIN FEATURE trial, a phase II ...
This study presents a valuable advance in reconstructing naturalistic speech from intracranial ECoG data using a dual-pathway model. The evidence supporting the claims of the authors is solid, ...
A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated an improved method for predicting treatment benefits in patients with hormone ...
The FEATURE study provides the first prospective validation of FDG-PET/CT and PERCIST response criteria in patients presenting with bone-only or bone-dominant metastatic breast cancer, opening the ...
New AI models integrating imaging, clinical, and molecular data from the TAILORx tissue biorepository show stronger prognostic performance than current methods to predict recurrence risk in ...
A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's immune system to target and eliminate cancer cells appeared to reduce the ...
Incorporating ICIs into platinum-doublet regimens improved OS and ORR in ES-SCLC patients with ECOG PS 2 to 3, but not in those with ECOG PS 0 to 1. The study found manageable adverse reactions, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results